0001562762-23-000033.txt : 20230203 0001562762-23-000033.hdr.sgml : 20230203 20230203123603 ACCESSION NUMBER: 0001562762-23-000033 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230130 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230203 DATE AS OF CHANGE: 20230203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxxinity, Inc. CENTRAL INDEX KEY: 0001851657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 862083865 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41058 FILM NUMBER: 23584856 BUSINESS ADDRESS: STREET 1: 505 ODYSSEY WAY CITY: EXPLORATION PARK STATE: FL ZIP: 32953 BUSINESS PHONE: (254) 244-5739 MAIL ADDRESS: STREET 1: 505 ODYSSEY WAY CITY: EXPLORATION PARK STATE: FL ZIP: 32953 8-K 1 20230130_8k.htm 20230130_8k
1717 Main St Ste 3388 Dallas TX 75201 false 0001851657 NASDAQ 0001851657 2023-01-30 2023-01-30
Washington, D.C. 20549
Date of Report (Date of earliest event reported):
January 30, 2023
Vaxxinity, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(IRS Employer
of incorporation)
File Number)
Identification No.)
505 Odyssey Way
Exploration Park, FL 32953
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number,
including area code: (
1717 Main St, Ste 3388
Dallas, TX 75201
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Class A Common Stock, par value $0.0001
per share
Global Market
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period
complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Resignation of Directors
On January 30, 2023, Mr. Greg Blatt and Mr.
James Chui resigned from their positions as members of
the Board of Directors (the “Board”) of Vaxxinity,
Inc. (the “Company”) and all committees of the Board on
which they served. Mr. Blatt and Mr.
Chui’s resignations were not a result of any disagreement between Mr.
Blatt or Mr. Chui and the Company on any matter relating to the Company’s
operations, policies or practices.
Increase in Board Size; Appointment of Directors
On January 31, 2023, the Board increased the size of the Board from seven members to nine members
and appointed Katherine Eade, Landon Ogilvie, James A. Smith and Gabrielle Toledano (the “New Members”)
as members of the Board, effective February 1, 2023.
The New Members will receive customary compensation from the Company for serving as non-
employee directors, in accordance with the Company’s Non-Employee Director Compensation Policy as
described in the Company’s Definitive Proxy Statement, under the heading “Director Compensation,” filed with
the U.S. Securities and Exchange Commission (the “SEC”) on May 2, 2022 and incorporated by reference
herein. However, the New Members will not receive an initial stock option award upon joining the Board and
will instead become eligible to receive stock option awards beginning with the Company’s next annual
stockholders meeting.
Effective upon the appointment of the New Members, the Board reconstituted its committees as follows:
Audit Committee: George Hornig (Chair), Peter Diamandis, Katherine Eade and James A. Smith
Compensation Committee: Gabrielle Toledano (Chair), Peter Diamandis and Landon Ogilvie
Nominating and Governance Committee: Peter Diamandis (Chair) and Gabrielle Toledano
The Board determined that each of the New Members is independent pursuant to the director
independence standards established under the Nasdaq Listing Rules and that Katherine Eade and James A.
Smith meet the additional requirements for service on the Company’s Audit Committee.
The Board designated
Landon Ogilvie as the Lead Independent Director.
There are no arrangements or understandings between the New Members and any other person pursuant
to which the New Members were appointed as directors. None of the New Members has any family
relationships with any of the Company’s directors or executive officers. There are no transactions to
which the
Company is a party and in which any of the New Members have a material interest that are required to be
disclosed under Item 404(a) of Regulation S-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
February 3, 2023
/s/ René Paula
Name: René Paula
General Counsel and Secretary
EX-101.SCH 2 vaxx-20230131.xsd 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 vaxx-20230131_lab.xml EX-101.PRE 4 vaxx-20230131_pre.xml XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Jan. 30, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Jan. 30, 2023
Entity Registrant Name Vaxxinity, Inc.
Entity Incorporation State Country Code DE
Entity File Number 333-261063
Entity Tax Identification Number 86-2083865
Entity Address Address Line 1 1717 Main St
Entity Address Address Line 2 Ste 3388
Entity Address City Or Town Dallas
Entity Address State Or Province TX
Entity Address Postal Zip Code 75201
City Area Code 254
Local Phone Number 244-5739
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Class A Common Stock, par value $0.0001 per share
Trading Symbol VAXX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Flag false
Entity Central Index Key 0001851657
XML 6 20230130_8k_htm.xml IDEA: XBRL DOCUMENT 0001851657 2023-01-30 2023-01-30 1717 Main St Ste 3388 Dallas TX 75201 false 0001851657 NASDAQ 8-K 2023-01-30 Vaxxinity, Inc. DE 333-261063 86-2083865 254 244-5739 false false false false Class A Common Stock, par value $0.0001 per share VAXX true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressAddressLine1, dei:EntityAddressAddressLine2, dei:EntityAddressCityOrTown, dei:EntityAddressPostalZipCode, dei:EntityAddressStateOrProvince, dei:SecurityExchangeName - 20230130_8k.htm 11, 12, 13, 14, 15, 18 20230130_8k.htm vaxx-20230131.xsd vaxx-20230131_lab.xml vaxx-20230131_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "20230130_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "20230130_8k.htm" ] }, "labelLink": { "local": [ "vaxx-20230131_lab.xml" ] }, "presentationLink": { "local": [ "vaxx-20230131_pre.xml" ] }, "schema": { "local": [ "vaxx-20230131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 8, "total": 8 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vaxx", "nsuri": "http://www.vaxxinity.com/20230131", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "20230130_8k.htm", "contextRef": "FROM_Jan30_2023_TO_Jan30_2023_Entity_0001851657", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "20230130_8k.htm", "contextRef": "FROM_Jan30_2023_TO_Jan30_2023_Entity_0001851657", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.vaxxinity.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001562762-23-000033-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001562762-23-000033-xbrl.zip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end